VRDN
NASDAQ · Biotechnology
Viridian Therapeutics Inc
$22.12
+0.54 (+2.50%)
Financial Highlights (FY 2026)
Revenue
91.68M
Net Income
-443,288,850
Gross Margin
2.8%
Profit Margin
-483.6%
Rev Growth
+242.1%
D/E Ratio
0.12
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 2.8% | 2.8% | 59.8% | 59.8% |
| Operating Margin | -512.9% | -89,116.5% | -5.8% | -4.8% |
| Profit Margin | -483.6% | -84,917.7% | -4.6% | -5.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 91.68M | 891.8K | 430.67M | 340.92M |
| Gross Profit | 2.53M | 24.6K | 257.57M | 203.89M |
| Operating Income | -470,222,937 | -794,781,643 | -24,891,292 | -16,489,487 |
| Net Income | -443,288,850 | -725,406,968 | -19,976,292 | -17,345,815 |
| Gross Margin | 2.8% | 2.8% | 59.8% | 59.8% |
| Operating Margin | -512.9% | -89,116.5% | -5.8% | -4.8% |
| Profit Margin | -483.6% | -84,917.7% | -4.6% | -5.1% |
| Rev Growth | +242.1% | -53.3% | -2.2% | +21.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 125.64M | 41.13M | 633.24M | 687.59M |
| Total Equity | 1.08B | 1.34B | 2.30B | 2.45B |
| D/E Ratio | 0.12 | 0.03 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -469,557,656 | -846,793,579 | -30,128,222 | -24,250,802 |
| Free Cash Flow | — | — | -23,390,816 | -14,209,915 |